Form 4 for TOVX Theriva Biologics, Inc.
Accepted 2023-06-07 00:00:00 ET · period of report 2023-06-06 · accession 0001104659-23-068719 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-06-07 | 2023-06-06 | TOVX | SHALLCROSS STEVEN A | CEO, CFO, Dir | P - Purchase | $0.63 | +26.0K | 236.0K | +12% | +$16.4K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-06-06 | P | A | 26,000 | $0.63 | 236,000 | D | — | — | (F1) The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $0.6015 through $0.6659, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. |